| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 87 | 2025 | 2508 | 8.420 |
Why?
|
| Receptor, ErbB-2 | 56 | 2025 | 514 | 6.920 |
Why?
|
| Trastuzumab | 33 | 2025 | 134 | 3.760 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 36 | 2025 | 1243 | 3.660 |
Why?
|
| Antineoplastic Agents | 24 | 2023 | 1711 | 2.500 |
Why?
|
| Quinazolines | 19 | 2023 | 175 | 2.270 |
Why?
|
| Antibodies, Monoclonal, Humanized | 22 | 2025 | 510 | 2.060 |
Why?
|
| Neoadjuvant Therapy | 27 | 2025 | 343 | 1.990 |
Why?
|
| Receptors, Estrogen | 31 | 2024 | 794 | 1.960 |
Why?
|
| Triple Negative Breast Neoplasms | 12 | 2024 | 234 | 1.740 |
Why?
|
| Aromatase Inhibitors | 7 | 2023 | 76 | 1.640 |
Why?
|
| Drug Resistance, Neoplasm | 18 | 2025 | 733 | 1.610 |
Why?
|
| Antineoplastic Agents, Hormonal | 6 | 2019 | 257 | 1.110 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 5 | 2023 | 74 | 0.980 |
Why?
|
| Estrogen Antagonists | 2 | 2022 | 104 | 0.780 |
Why?
|
| Female | 85 | 2025 | 66802 | 0.780 |
Why?
|
| Arthralgia | 2 | 2019 | 56 | 0.760 |
Why?
|
| Neoplasm Staging | 13 | 2024 | 1275 | 0.700 |
Why?
|
| Biomarkers, Tumor | 12 | 2025 | 1534 | 0.700 |
Why?
|
| PTEN Phosphohydrolase | 3 | 2017 | 260 | 0.680 |
Why?
|
| Cholecalciferol | 1 | 2019 | 23 | 0.640 |
Why?
|
| Humans | 97 | 2025 | 125287 | 0.610 |
Why?
|
| Brain Neoplasms | 5 | 2024 | 1312 | 0.580 |
Why?
|
| Middle Aged | 39 | 2025 | 26788 | 0.570 |
Why?
|
| Chemotherapy, Adjuvant | 12 | 2024 | 366 | 0.540 |
Why?
|
| Antineoplastic Agents, Immunological | 3 | 2025 | 115 | 0.540 |
Why?
|
| Alopecia | 1 | 2017 | 39 | 0.530 |
Why?
|
| Aged | 29 | 2025 | 19700 | 0.530 |
Why?
|
| Quinolines | 4 | 2024 | 103 | 0.520 |
Why?
|
| Scalp | 1 | 2017 | 57 | 0.520 |
Why?
|
| ErbB Receptors | 6 | 2014 | 283 | 0.520 |
Why?
|
| Molecular Targeted Therapy | 9 | 2025 | 375 | 0.510 |
Why?
|
| Hypothermia, Induced | 1 | 2017 | 170 | 0.490 |
Why?
|
| Paclitaxel | 4 | 2024 | 130 | 0.470 |
Why?
|
| Carcinoma | 2 | 2015 | 290 | 0.470 |
Why?
|
| Treatment Outcome | 21 | 2025 | 12293 | 0.470 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2024 | 1117 | 0.450 |
Why?
|
| Signal Transduction | 19 | 2025 | 4591 | 0.450 |
Why?
|
| Adult | 29 | 2025 | 29579 | 0.440 |
Why?
|
| Sirolimus | 2 | 2014 | 227 | 0.440 |
Why?
|
| Taxoids | 5 | 2024 | 67 | 0.430 |
Why?
|
| Endoribonucleases | 2 | 2024 | 83 | 0.420 |
Why?
|
| Cell Line, Tumor | 19 | 2024 | 3415 | 0.420 |
Why?
|
| Aged, 80 and over | 12 | 2021 | 6536 | 0.400 |
Why?
|
| Antibodies, Monoclonal | 5 | 2023 | 1026 | 0.400 |
Why?
|
| Neoplastic Cells, Circulating | 3 | 2019 | 74 | 0.370 |
Why?
|
| Disease-Free Survival | 7 | 2024 | 880 | 0.360 |
Why?
|
| Mastectomy | 5 | 2021 | 64 | 0.360 |
Why?
|
| Data Interpretation, Statistical | 1 | 2012 | 231 | 0.350 |
Why?
|
| Proteogenomics | 2 | 2022 | 69 | 0.350 |
Why?
|
| Xenograft Model Antitumor Assays | 10 | 2018 | 914 | 0.340 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 2 | 2021 | 121 | 0.330 |
Why?
|
| Positron Emission Tomography Computed Tomography | 3 | 2025 | 77 | 0.320 |
Why?
|
| Maytansine | 2 | 2021 | 3 | 0.300 |
Why?
|
| Fluorodeoxyglucose F18 | 5 | 2025 | 147 | 0.290 |
Why?
|
| Immunosuppressive Agents | 1 | 2012 | 645 | 0.290 |
Why?
|
| Nitriles | 4 | 2024 | 145 | 0.280 |
Why?
|
| Triazoles | 4 | 2024 | 139 | 0.280 |
Why?
|
| Phosphatidylinositol 3-Kinases | 5 | 2019 | 339 | 0.270 |
Why?
|
| Neoplasms, Hormone-Dependent | 3 | 2018 | 101 | 0.260 |
Why?
|
| Neoplasm Recurrence, Local | 5 | 2023 | 1153 | 0.260 |
Why?
|
| Mice, Nude | 9 | 2018 | 725 | 0.250 |
Why?
|
| Indoles | 2 | 2018 | 191 | 0.250 |
Why?
|
| Receptors, Progesterone | 8 | 2018 | 877 | 0.240 |
Why?
|
| Pyridines | 3 | 2021 | 235 | 0.230 |
Why?
|
| Gene Expression Regulation, Neoplastic | 5 | 2017 | 1980 | 0.230 |
Why?
|
| Piperazines | 3 | 2021 | 242 | 0.230 |
Why?
|
| Pyroptosis | 1 | 2024 | 26 | 0.230 |
Why?
|
| RNA, Double-Stranded | 1 | 2024 | 63 | 0.230 |
Why?
|
| Proteomics | 2 | 2025 | 507 | 0.220 |
Why?
|
| Anthracyclines | 2 | 2017 | 37 | 0.220 |
Why?
|
| Lymphatic Metastasis | 4 | 2013 | 418 | 0.220 |
Why?
|
| Heat Shock Transcription Factors | 1 | 2023 | 19 | 0.210 |
Why?
|
| Catechin | 2 | 2014 | 13 | 0.210 |
Why?
|
| Mastectomy, Segmental | 2 | 2021 | 27 | 0.210 |
Why?
|
| Proteostasis | 1 | 2023 | 34 | 0.210 |
Why?
|
| Immunoconjugates | 1 | 2023 | 38 | 0.210 |
Why?
|
| Circulating Tumor DNA | 1 | 2023 | 35 | 0.210 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2023 | 145 | 0.200 |
Why?
|
| Tamoxifen | 6 | 2018 | 363 | 0.200 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2023 | 158 | 0.200 |
Why?
|
| Tetrahydronaphthalenes | 1 | 2022 | 29 | 0.200 |
Why?
|
| Animals | 20 | 2024 | 34299 | 0.200 |
Why?
|
| Bridged-Ring Compounds | 2 | 2024 | 17 | 0.200 |
Why?
|
| Epidermal Growth Factor | 2 | 2021 | 123 | 0.200 |
Why?
|
| Gene Expression | 5 | 2020 | 1553 | 0.190 |
Why?
|
| Selective Estrogen Receptor Modulators | 1 | 2022 | 60 | 0.190 |
Why?
|
| Prognosis | 10 | 2020 | 4678 | 0.190 |
Why?
|
| Phosphatidylinositol 3-Kinase | 1 | 2021 | 25 | 0.190 |
Why?
|
| Mammary Neoplasms, Animal | 1 | 2022 | 139 | 0.190 |
Why?
|
| Protein Kinase Inhibitors | 4 | 2025 | 543 | 0.190 |
Why?
|
| Neoplasms, Second Primary | 1 | 2023 | 146 | 0.180 |
Why?
|
| Lung Diseases, Interstitial | 1 | 2023 | 150 | 0.180 |
Why?
|
| Cyclin-Dependent Kinase 6 | 1 | 2021 | 44 | 0.180 |
Why?
|
| Cyclin-Dependent Kinase 4 | 1 | 2021 | 59 | 0.180 |
Why?
|
| Mutation | 7 | 2020 | 5900 | 0.170 |
Why?
|
| Enzyme Inhibitors | 1 | 2023 | 587 | 0.170 |
Why?
|
| Survival Analysis | 5 | 2020 | 1493 | 0.170 |
Why?
|
| Mevalonic Acid | 1 | 2019 | 19 | 0.160 |
Why?
|
| Pneumonia | 1 | 2023 | 325 | 0.160 |
Why?
|
| Drug Administration Schedule | 3 | 2019 | 728 | 0.160 |
Why?
|
| Genes, erbB-2 | 2 | 2010 | 37 | 0.160 |
Why?
|
| Neoplasm Metastasis | 3 | 2016 | 705 | 0.160 |
Why?
|
| Capecitabine | 2 | 2019 | 16 | 0.160 |
Why?
|
| Cinnamates | 1 | 2018 | 15 | 0.150 |
Why?
|
| Mice | 15 | 2024 | 17736 | 0.150 |
Why?
|
| Androstadienes | 2 | 2017 | 50 | 0.150 |
Why?
|
| Risk Factors | 4 | 2021 | 10283 | 0.150 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 12 | 1 | 2018 | 19 | 0.150 |
Why?
|
| Up-Regulation | 4 | 2014 | 875 | 0.150 |
Why?
|
| Lymphocytes | 1 | 2019 | 408 | 0.140 |
Why?
|
| Electronic Health Records | 1 | 2024 | 723 | 0.140 |
Why?
|
| Receptors, Calcitriol | 1 | 2017 | 69 | 0.140 |
Why?
|
| Early Termination of Clinical Trials | 1 | 2017 | 16 | 0.140 |
Why?
|
| Quality of Life | 3 | 2017 | 1946 | 0.140 |
Why?
|
| Radiopharmaceuticals | 3 | 2025 | 168 | 0.140 |
Why?
|
| Interleukin-1beta | 1 | 2017 | 162 | 0.130 |
Why?
|
| Fluorouracil | 2 | 2014 | 129 | 0.130 |
Why?
|
| Hepatocyte Nuclear Factor 3-alpha | 1 | 2016 | 48 | 0.130 |
Why?
|
| Precision Medicine | 1 | 2019 | 321 | 0.130 |
Why?
|
| Single-Cell Analysis | 1 | 2019 | 288 | 0.130 |
Why?
|
| Diphosphonates | 1 | 2016 | 38 | 0.130 |
Why?
|
| Dasatinib | 1 | 2016 | 41 | 0.130 |
Why?
|
| Lung Neoplasms | 2 | 2024 | 1654 | 0.130 |
Why?
|
| Gene Expression Profiling | 4 | 2016 | 1756 | 0.130 |
Why?
|
| Bone Density Conservation Agents | 1 | 2016 | 51 | 0.120 |
Why?
|
| Combined Modality Therapy | 2 | 2021 | 1236 | 0.120 |
Why?
|
| Receptors, Cell Surface | 1 | 2018 | 476 | 0.120 |
Why?
|
| Interleukin-8 | 1 | 2016 | 210 | 0.120 |
Why?
|
| Dietary Supplements | 1 | 2019 | 471 | 0.120 |
Why?
|
| Primary Prevention | 1 | 2017 | 172 | 0.120 |
Why?
|
| Neoplasm Transplantation | 2 | 2019 | 383 | 0.120 |
Why?
|
| Carboplatin | 3 | 2022 | 77 | 0.120 |
Why?
|
| Transcriptome | 3 | 2016 | 977 | 0.120 |
Why?
|
| Medication Adherence | 1 | 2019 | 400 | 0.120 |
Why?
|
| Imidazoles | 1 | 2016 | 205 | 0.120 |
Why?
|
| Predictive Value of Tests | 4 | 2025 | 2174 | 0.110 |
Why?
|
| Deoxycytidine | 1 | 2014 | 78 | 0.110 |
Why?
|
| Tea | 1 | 2014 | 15 | 0.110 |
Why?
|
| Apoptosis | 4 | 2019 | 1816 | 0.110 |
Why?
|
| Breast | 3 | 2022 | 213 | 0.110 |
Why?
|
| Time Factors | 6 | 2021 | 6311 | 0.110 |
Why?
|
| Tumor Microenvironment | 3 | 2025 | 565 | 0.110 |
Why?
|
| Acneiform Eruptions | 1 | 2013 | 4 | 0.110 |
Why?
|
| Receptor, IGF Type 1 | 2 | 2010 | 92 | 0.100 |
Why?
|
| Pyrroles | 1 | 2014 | 184 | 0.100 |
Why?
|
| Drug Eruptions | 1 | 2013 | 32 | 0.100 |
Why?
|
| Estrogen Receptor alpha | 1 | 2016 | 458 | 0.100 |
Why?
|
| Pilot Projects | 3 | 2024 | 1397 | 0.100 |
Why?
|
| Cell Proliferation | 6 | 2018 | 2371 | 0.100 |
Why?
|
| Plant Extracts | 1 | 2014 | 118 | 0.100 |
Why?
|
| Estrogens | 3 | 2018 | 505 | 0.100 |
Why?
|
| Mucin-4 | 1 | 2012 | 11 | 0.100 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2014 | 283 | 0.100 |
Why?
|
| Mammaplasty | 1 | 2013 | 53 | 0.100 |
Why?
|
| Estradiol | 4 | 2018 | 530 | 0.100 |
Why?
|
| Jejunal Neoplasms | 1 | 2012 | 5 | 0.100 |
Why?
|
| Age Factors | 3 | 2021 | 2819 | 0.100 |
Why?
|
| Phyllodes Tumor | 1 | 2012 | 11 | 0.100 |
Why?
|
| Jejunal Diseases | 1 | 2012 | 15 | 0.100 |
Why?
|
| Biomarkers | 3 | 2020 | 3093 | 0.100 |
Why?
|
| Risk Assessment | 1 | 2021 | 3439 | 0.100 |
Why?
|
| Fibroblasts | 1 | 2016 | 888 | 0.100 |
Why?
|
| Everolimus | 1 | 2012 | 50 | 0.090 |
Why?
|
| Integrin beta1 | 1 | 2011 | 56 | 0.090 |
Why?
|
| Bone Neoplasms | 1 | 2016 | 427 | 0.090 |
Why?
|
| Intussusception | 1 | 2012 | 48 | 0.090 |
Why?
|
| Clinical Trials, Phase II as Topic | 3 | 2020 | 73 | 0.090 |
Why?
|
| MCF-7 Cells | 3 | 2018 | 222 | 0.090 |
Why?
|
| Postmenopause | 2 | 2024 | 126 | 0.090 |
Why?
|
| Phosphorylation | 4 | 2019 | 1637 | 0.090 |
Why?
|
| Triazines | 1 | 2010 | 30 | 0.090 |
Why?
|
| Women's Health | 1 | 2012 | 134 | 0.090 |
Why?
|
| Cross-Over Studies | 1 | 2012 | 313 | 0.090 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2021 | 1064 | 0.090 |
Why?
|
| Genetic Testing | 1 | 2017 | 1012 | 0.090 |
Why?
|
| Guilt | 1 | 2010 | 15 | 0.080 |
Why?
|
| Frozen Sections | 1 | 2010 | 26 | 0.080 |
Why?
|
| Spirituality | 1 | 2010 | 48 | 0.080 |
Why?
|
| Mice, SCID | 3 | 2019 | 586 | 0.080 |
Why?
|
| Young Adult | 2 | 2021 | 9058 | 0.080 |
Why?
|
| Ki-67 Antigen | 2 | 2024 | 114 | 0.080 |
Why?
|
| Self Concept | 1 | 2010 | 155 | 0.080 |
Why?
|
| Remission Induction | 2 | 2020 | 291 | 0.080 |
Why?
|
| Neoplasms | 1 | 2023 | 2799 | 0.080 |
Why?
|
| Prospective Studies | 4 | 2023 | 6160 | 0.070 |
Why?
|
| Pyrazoles | 1 | 2010 | 306 | 0.070 |
Why?
|
| Positron-Emission Tomography | 2 | 2023 | 305 | 0.070 |
Why?
|
| Research Design | 1 | 2012 | 692 | 0.070 |
Why?
|
| Survivors | 1 | 2010 | 338 | 0.070 |
Why?
|
| Phenotype | 3 | 2013 | 4268 | 0.070 |
Why?
|
| DNA Repair | 1 | 2010 | 587 | 0.070 |
Why?
|
| RNA, Small Interfering | 3 | 2016 | 670 | 0.070 |
Why?
|
| Heterografts | 2 | 2018 | 175 | 0.070 |
Why?
|
| Tissue Distribution | 2 | 2019 | 391 | 0.060 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 2018 | 145 | 0.060 |
Why?
|
| TOR Serine-Threonine Kinases | 2 | 2020 | 436 | 0.060 |
Why?
|
| Calibration | 1 | 2024 | 89 | 0.060 |
Why?
|
| Cell Survival | 2 | 2018 | 819 | 0.060 |
Why?
|
| Follow-Up Studies | 3 | 2019 | 5169 | 0.050 |
Why?
|
| Endoplasmic Reticulum Stress | 1 | 2024 | 120 | 0.050 |
Why?
|
| src-Family Kinases | 2 | 2016 | 91 | 0.050 |
Why?
|
| B7-H1 Antigen | 1 | 2024 | 120 | 0.050 |
Why?
|
| NLR Family, Pyrin Domain-Containing 3 Protein | 1 | 2024 | 113 | 0.050 |
Why?
|
| Disease Progression | 3 | 2014 | 2081 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2017 | 493 | 0.050 |
Why?
|
| Purines | 1 | 2023 | 116 | 0.050 |
Why?
|
| X-ray Repair Cross Complementing Protein 1 | 1 | 2022 | 21 | 0.050 |
Why?
|
| Neoplasm, Residual | 1 | 2023 | 121 | 0.050 |
Why?
|
| Inflammasomes | 1 | 2024 | 150 | 0.050 |
Why?
|
| Mitogen-Activated Protein Kinases | 2 | 2014 | 210 | 0.050 |
Why?
|
| Survival Rate | 2 | 2019 | 2047 | 0.050 |
Why?
|
| Amenorrhea | 1 | 2021 | 20 | 0.050 |
Why?
|
| Mice, Inbred NOD | 2 | 2013 | 299 | 0.050 |
Why?
|
| Depression | 1 | 2010 | 1236 | 0.050 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2024 | 348 | 0.040 |
Why?
|
| Proportional Hazards Models | 2 | 2014 | 1356 | 0.040 |
Why?
|
| Radiotherapy | 1 | 2021 | 138 | 0.040 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2023 | 586 | 0.040 |
Why?
|
| Homologous Recombination | 1 | 2020 | 92 | 0.040 |
Why?
|
| Biopsy, Large-Core Needle | 1 | 2020 | 31 | 0.040 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2020 | 69 | 0.040 |
Why?
|
| Single Photon Emission Computed Tomography Computed Tomography | 1 | 2019 | 7 | 0.040 |
Why?
|
| Keratins | 1 | 2019 | 54 | 0.040 |
Why?
|
| Tumor Cells, Cultured | 1 | 2021 | 1077 | 0.040 |
Why?
|
| Retrospective Studies | 3 | 2024 | 16345 | 0.040 |
Why?
|
| Cisplatin | 1 | 2020 | 249 | 0.040 |
Why?
|
| United States | 3 | 2021 | 10875 | 0.040 |
Why?
|
| Leukocyte Common Antigens | 1 | 2019 | 91 | 0.040 |
Why?
|
| Craniotomy | 1 | 2019 | 109 | 0.040 |
Why?
|
| Mechanistic Target of Rapamycin Complex 1 | 1 | 2019 | 166 | 0.040 |
Why?
|
| Gene Amplification | 1 | 2019 | 236 | 0.040 |
Why?
|
| Cell Separation | 1 | 2019 | 230 | 0.040 |
Why?
|
| Carrier Proteins | 1 | 2023 | 1033 | 0.040 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2012 | 1033 | 0.040 |
Why?
|
| Cohort Studies | 2 | 2019 | 4835 | 0.040 |
Why?
|
| Epigenesis, Genetic | 1 | 2022 | 702 | 0.040 |
Why?
|
| Oncogene Addiction | 1 | 2017 | 3 | 0.040 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2010 | 1292 | 0.040 |
Why?
|
| Down-Regulation | 1 | 2020 | 690 | 0.030 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2018 | 129 | 0.030 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2019 | 772 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2019 | 681 | 0.030 |
Why?
|
| Transplantation, Heterologous | 2 | 2007 | 261 | 0.030 |
Why?
|
| DNA Methylation | 1 | 2022 | 1051 | 0.030 |
Why?
|
| Vitamin D | 1 | 2017 | 161 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2015 | 172 | 0.030 |
Why?
|
| Disease Models, Animal | 2 | 2015 | 4405 | 0.030 |
Why?
|
| Cell Count | 1 | 2014 | 252 | 0.030 |
Why?
|
| Biological Availability | 1 | 2014 | 137 | 0.030 |
Why?
|
| Hepatocyte Growth Factor | 1 | 2014 | 30 | 0.030 |
Why?
|
| South America | 1 | 2014 | 39 | 0.030 |
Why?
|
| Patient Outcome Assessment | 1 | 2014 | 94 | 0.030 |
Why?
|
| Intention to Treat Analysis | 1 | 2014 | 65 | 0.030 |
Why?
|
| Doxycycline | 1 | 2014 | 117 | 0.030 |
Why?
|
| South Africa | 1 | 2014 | 99 | 0.030 |
Why?
|
| Australia | 1 | 2014 | 139 | 0.030 |
Why?
|
| Placebos | 1 | 2014 | 241 | 0.030 |
Why?
|
| Gene Knockdown Techniques | 1 | 2014 | 367 | 0.030 |
Why?
|
| North America | 1 | 2014 | 242 | 0.030 |
Why?
|
| Hospitals, Public | 1 | 2013 | 41 | 0.030 |
Why?
|
| Random Allocation | 1 | 2014 | 439 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2020 | 2901 | 0.030 |
Why?
|
| Europe | 1 | 2014 | 357 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 1 | 2019 | 1763 | 0.030 |
Why?
|
| Ploidies | 1 | 2012 | 37 | 0.030 |
Why?
|
| Cetuximab | 1 | 2012 | 13 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2014 | 822 | 0.020 |
Why?
|
| Linear Models | 1 | 2014 | 686 | 0.020 |
Why?
|
| Maximum Tolerated Dose | 1 | 2012 | 163 | 0.020 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2012 | 85 | 0.020 |
Why?
|
| Receptor, ErbB-3 | 1 | 2011 | 16 | 0.020 |
Why?
|
| Insurance Coverage | 1 | 2013 | 120 | 0.020 |
Why?
|
| Focal Adhesion Kinase 1 | 1 | 2011 | 25 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2014 | 408 | 0.020 |
Why?
|
| Breast Neoplasms, Male | 1 | 2011 | 15 | 0.020 |
Why?
|
| Oncogene Protein v-akt | 1 | 2011 | 30 | 0.020 |
Why?
|
| Vulnerable Populations | 1 | 2013 | 136 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2023 | 3603 | 0.020 |
Why?
|
| Tumor Burden | 1 | 2012 | 231 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2013 | 775 | 0.020 |
Why?
|
| Triglycerides | 1 | 2014 | 575 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2012 | 434 | 0.020 |
Why?
|
| Cyclin D1 | 1 | 2011 | 113 | 0.020 |
Why?
|
| Cholesterol | 1 | 2014 | 540 | 0.020 |
Why?
|
| NIH 3T3 Cells | 1 | 2010 | 92 | 0.020 |
Why?
|
| Receptor, Insulin | 1 | 2010 | 67 | 0.020 |
Why?
|
| Epirubicin | 1 | 2010 | 5 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2017 | 3307 | 0.020 |
Why?
|
| Immunoblotting | 1 | 2010 | 312 | 0.020 |
Why?
|
| Patient Selection | 1 | 2014 | 697 | 0.020 |
Why?
|
| Antibodies | 1 | 2011 | 374 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2010 | 405 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2010 | 317 | 0.020 |
Why?
|
| Personality Inventory | 1 | 2010 | 168 | 0.020 |
Why?
|
| Enzyme Activation | 1 | 2010 | 626 | 0.020 |
Why?
|
| Genomics | 1 | 2017 | 1520 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2012 | 1428 | 0.020 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2010 | 340 | 0.020 |
Why?
|
| Cell Cycle | 1 | 2011 | 625 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2017 | 2652 | 0.020 |
Why?
|
| Transfection | 1 | 2010 | 1076 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2012 | 1691 | 0.020 |
Why?
|
| ROC Curve | 1 | 2010 | 571 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2012 | 1634 | 0.020 |
Why?
|
| Cyclophosphamide | 1 | 2010 | 412 | 0.020 |
Why?
|
| Comorbidity | 1 | 2013 | 1528 | 0.020 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2011 | 559 | 0.020 |
Why?
|
| Brain | 1 | 2019 | 3010 | 0.020 |
Why?
|
| Drug Synergism | 1 | 2008 | 227 | 0.020 |
Why?
|
| Smoking | 1 | 2013 | 1047 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2013 | 1562 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2017 | 3175 | 0.020 |
Why?
|
| Adaptation, Psychological | 1 | 2010 | 449 | 0.020 |
Why?
|
| Receptors, Growth Factor | 1 | 2005 | 35 | 0.020 |
Why?
|
| Estrogen Receptor Modulators | 1 | 2005 | 38 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2010 | 1104 | 0.020 |
Why?
|
| Cell Division | 1 | 2007 | 779 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2013 | 3751 | 0.020 |
Why?
|
| Male | 2 | 2024 | 61544 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2006 | 1704 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 2008 | 1704 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 2013 | 3057 | 0.010 |
Why?
|
| Surveys and Questionnaires | 1 | 2010 | 3741 | 0.010 |
Why?
|